Atorvastatin intermediates are key chemical building blocks used in the multi‑step synthesis of atorvastatin, a widely prescribed HMG‑CoA reductase inhibitor for cholesterol management. These intermediates, such as ethyl (R)‑4‑cyano‑3‑hydroxybutyrate and specific dioxane esters, are designed with precise stereochemistry to ensure high yield and optical purity in downstream transformations. Their correct configuration and high purity are essential for achieving the stringent enantiomeric and diastereomeric requirements of atorvastatin active pharmaceutical ingredient (API), making them indispensable for both commercial production and generics manufacturing.
Atorvastatin Intermediates Characteristics
High Stereochemical Accuracy: Precisely defined chiral centers ensure optimal conversion and minimal by-product formation in atorvastatin synthesis.
Exceptional Chemical Purity: Purity levels exceed 99.5 %, supporting high-quality API production with fewer downstream purification steps.
Robust and Scalable Process: Reliable production methods provide consistent supply for both laboratory research and commercial manufacturing.
| Name | CAS Number | Molecular Formula | Molecular Weight（g/mol） | Chemical Structure |
| Atorvastatin Calcium | 134523-00-5 | C₆₆H₆₈CaF₂N₄O₁₀ | 1209.42 |  |
| Atorvastatin Lactone | 125971-94-0 | C₃₃H₃₅FN₂O₅ | 558.64 |  |
Atorvastatin intermediates serve as essential molecular building blocks in the multi‑step organic synthesis of atorvastatin, a widely prescribed cholesterol‑lowering statin. These intermediates, especially optically active chiral fragments like (S)‑4‑chloro‑3‑hydroxybutyronitrile or its hydroxynitrile derivatives, are strategically crafted to introduce and control specific stereochemistry early in the synthetic sequence. Their configured stereogenic centers guide subsequent bond‑forming reactions, enabling the assembly of the core atorvastatin structure with high enantiomeric purity and minimized by‑product formation. By simplifying the complex synthetic route, these intermediates streamline process efficiency, improve overall yields, and ensure consistent quality of the final active pharmaceutical ingredient (API).
Atorvastatin calcium (cholesterol‑lowering statin)
Intermediates like (4R,6R)‑tert‑butyl‑6‑cyanomethyl‑dioxane acetate are critical precursors enabling the stereospecific construction of the atorvastatin API for hypercholesterolemia therapy.
Rosuvastatin and Pitavastatin (other statins)
Shared chiral intermediates for the dihydroxy side chain help form the pharmacophore of multiple HMG‑CoA reductase inhibitors used in cardiovascular disease management.
Atorvastatin calcium analogs (cardiovascular risk reduction)
Optically active hydroxy nitrile intermediates serve as building blocks in synthetic routes that ensure high enantiomeric purity of statins treating high LDL cholesterol.
B608, #25 Shenbin Rd, Minhang District, Shanghai, China
English
